Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cervarix to roll out to 300,000 more girls

This article was originally published in Scrip

Executive Summary

A further 300,000 girls will receive GlaxoSmithKline's Cervarix this year under plans by the UK's Department of Health to extend the national HPV vaccination programme to girls aged 17 to 18 from September. They will be vaccinated alongside the routine vaccination of girls aged between 12 and 13, which also starts in September. This means that girls who would not otherwise have been included in the catch-up programme will now be vaccinated this school year; the catch-up programme is due to start as planned in 2009-10 in those aged between 15 to 18. "This could save an additional 400 lives," commented health minister Dawn Primarolo. Primary care trusts will receive an additional £10 million in the 2008-09 financial year to implement the extra programme. Cervarix is designed to protect against the two strains of the HPV virus which cause 70% of cases of cervical cancer, the second most common cancer in women.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC000421

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel